Brief: ARS Pharmaceuticals Provides Commercial And Financial Updates
24/06/2026 23:25
BRIEF-ARS Pharmaceuticals Provides Commercial And Financial Updates June 24 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:
ARS PHARMACEUTICALS PROVIDES COMMERCIAL AND FINANCIAL UPDATES
ARS PHARMACEUTICALS INC: REAFFIRMS NEFFY BASE BUSINESS SUPPORTS A PATH TO CASH-FLOW BREAKEVEN IN 2027
ARS PHARMACEUTICALS INC: TOTAL 2026 CASH-BASED OPERATING EXPENSES, EXCLUDING COGS, LOWERED TO $248 MILLION
ARS PHARMACEUTICALS - NO NEW COMMERCIAL FORMULARY ADDITIONS FOR NEFFY IN JULY 1, 2026 CYCLE
Source text: ID:nGNX3jjpJc
Further company coverage: SPRY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ARS Pharmaceuticals
See all newsARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doubles
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle